• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Chin Eric claimed ownership of 10,000 units of Restricted Stock (SEC Form 3)

    6/6/25 9:29:04 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Chin Eric

    (Last) (First) (Middle)
    17571 VON KARMAN AVE

    (Street)
    IRVINE CA 92614

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/04/2025
    3. Issuer Name and Ticker or Trading Symbol
    BIOMERICA INC [ BMRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Restricted Stock(1) 10,000(2) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Restricted Stock grant under the 2024 Stock Incentive Plan. The Reporting Person, was elected to and joined the Board of Directors as an independent Board Member on June 4, 2025.
    2. The Restricted stocks vest in full on December 13, 2025, provided the Reporting Person remains continuously employed on such date.
    /s/ Eric Chin 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

      Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin's appointment strengthens Biomerica's corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company's Board of Directors, effective June 4, 2025. Mr. Chin will serve

      6/6/25 9:30:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

      IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

      2/21/24 8:19:00 AM ET
      $BMRA
      $LH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Medical Specialities
    • Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

      Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

      1/23/24 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      11/14/24 4:19:51 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      2/14/24 9:00:06 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Biomerica Inc.

      SC 13G - BIOMERICA INC (0000073290) (Subject)

      2/9/24 3:06:57 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Chin Eric claimed ownership of 10,000 units of Restricted Stock (SEC Form 3)

      3 - BIOMERICA INC (0000073290) (Issuer)

      6/6/25 9:29:04 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:09 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    SEC Filings

    See more

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomerica Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      6/6/25 9:29:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      4/16/25 9:00:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      4/14/25 4:15:33 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

      Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin's appointment strengthens Biomerica's corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company's Board of Directors, effective June 4, 2025. Mr. Chin will serve

      6/6/25 9:30:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica's inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology

      Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test

      6/5/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

      Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today anno

      5/22/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Financials

    Live finance-specific insights

    See more
    • Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

      InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

      1/13/23 6:39:00 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care